Medicamen Biotech Limited

NSE MEDICAMEQ.NS

Medicamen Biotech Limited Operating Income Margin for the year ending March 31, 2024: 28.82%

Medicamen Biotech Limited Operating Income Margin is 28.82% for the year ending March 31, 2024, a 130.29% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Medicamen Biotech Limited Operating Income Margin for the year ending March 31, 2023 was 12.52%, a -19.25% change year over year.
Medicamen Biotech Limited Operating Income Margin for the year ending March 31, 2022 was 15.50%, a 3.85% change year over year.
Medicamen Biotech Limited Operating Income Margin for the year ending March 31, 2021 was 14.93%, a 11.37% change year over year.
Medicamen Biotech Limited Operating Income Margin for the year ending March 31, 2020 was 13.40%, a 6.37% change year over year.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

NSE: MEDICAMEQ.NS

Medicamen Biotech Limited

CEO	Mr. Rajesh Madan B. Pharma
IPO Date	Oct. 27, 2021
Location	India
Headquarters	1506, Chiranjiv Tower
Employees	378
Sector	Consumers Staples
Industries Personal Care Cleaning Supplies Cosmetics Dental Care Drugstores & Retail Pharmacies Eyewear Non-Alcoholic Beverages Pharmaceuticals

Description

Medicamen Biotech Limited manufactures and sells pharmaceutical formulations in India. The company offers its products in various forms, including tablets, capsules, liquid and dry syrups, and ointments. It also provides oral rehydration solution, mouth wash, and dental care products. The company was incorporated in 1993 and is based in New Delhi, India.

Key trends

Past 5 years